Cargando…

Antibody response to graded dosing of coronavirus disease 2019 messenger RNA vaccines after allergic reaction to first dose

Detalles Bibliográficos
Autores principales:	Van Meerbeke, Sara W., Fajt, Merritt L., Marini, Rachel V., Domsic, Robyn T., Petrov, Andrej A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112645/ https://www.ncbi.nlm.nih.gov/pubmed/35595005 http://dx.doi.org/10.1016/j.anai.2022.05.004

Ejemplares similares

Authors' response
por: Van Meerbeke, Sara W., et al.
Publicado: (2022)

Antibody response to coronavirus disease 2019 vaccines after allergic reaction to first dose: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine( )
por: Maron, Jenny S, et al.
Publicado: (2022)

Coronavirus disease 2019 messenger RNA vaccine skin tests and serum histamine levels in allergic reactions
por: Kohli-Pamnani, Anita, et al.
Publicado: (2022)

Outcomes of allergic-type reactions after messenger RNA coronavirus disease 2019 vaccination at 3 military medical centers
por: St. Clair, Benjamin D., et al.
Publicado: (2022)

TOLERABILITY OF GRADED CORONAVIRUS DISEASE 2019 MRNA VACCINE DOSING
por: Hamel, B., et al.
Publicado: (2022)

Sustained Myocarditis following Messenger RNA Vaccination against Coronavirus Disease 2019: Relation to Neutralizing Antibody and Amelioration by Low-Dose Booster Vaccination
por: Miyazaki, Koji, et al.
Publicado: (2023)

Cohort experience of second messenger RNA vaccine dose tolerance after an initial-dose reaction
por: Eastman, Jacqueline, et al.
Publicado: (2022)

Split dosing of coronavirus disease 2019 vaccines provides noninferior antibody responsiveness to conventional vaccine dosing
por: Musa, Amal, et al.
Publicado: (2022)

Biphasic anaphylaxis after first dose of messenger RNA coronavirus disease 2019 vaccine with positive polysorbate 80 skin testing result
por: Pitlick, Mitchell M., et al.
Publicado: (2021)

Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
por: Vanijcharoenkarn, Kristine, et al.
Publicado: (2021)

Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2021)

Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions
por: Pitlick, Mitchell M., et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients
por: Strauss, Alexandra T., et al.
Publicado: (2022)

Split-dosing of coronavirus disease 2019 vaccines
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

This Month in JAAD International: August 2022: Cutaneous reactions to COVID-19 messenger RNA booster dose vaccination
por: Kantor, Jonathan
Publicado: (2022)

Convalescent Plasma for Coronavirus Disease 2019: Dose is the Key
por: Yu, Jiangquan, et al.
Publicado: (2021)

Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination
por: Dages, Kelley N., et al.
Publicado: (2021)

Co-existence of vocal cord dysfunction with pulmonary conditions other than asthma: A case series
por: Fajt, Merritt L., et al.
Publicado: (2018)

Successful fractionated undiluted doses of COVID‐19 vaccine in five cases of suspected allergic reactions to the first dose
por: Rivolta, Federica, et al.
Publicado: (2022)

Allergic diseases of the skin and drug allergies – 2019. Higher doses for heavy hives
por: Godse, Kiran
Publicado: (2013)

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination
por: Chen, Xuemin, et al.
Publicado: (2023)

Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience
por: Kaplan, Blanka, et al.
Publicado: (2022)

Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment
por: Carbillon, Lionel, et al.
Publicado: (2021)

Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series
por: Peigottu, Maria Francesca, et al.
Publicado: (2021)

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma
por: Greenberg, Ross S., et al.
Publicado: (2021)

COVID-19 VACCINE ADMINISTRATION IN PATIENTS WITH FIRST-DOSE ADVERSE REACTIONS OR HISTORY OF SEVERE ALLERGIC REACTION
por: Vanijcharoenkarn, K., et al.
Publicado: (2022)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies
por: Corey, Kristen B., et al.
Publicado: (2022)

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination
por: Kim, A-Sol, et al.
Publicado: (2023)

Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines: Not the usual suspects?
por: de Chaisemartin, Luc, et al.
Publicado: (2022)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Second-dose COVID-19 vaccines are well tolerated in patients with allergic reactions to the first dose – a single center experience
por: Puxkandl, Viktoria, et al.
Publicado: (2022)

Evaluation of anaphylaxis risk by skin testing with coronavirus disease 2019 messenger RNA vaccines on patients with anaphylaxis
por: Pienkowski, Marek M., et al.
Publicado: (2022)

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age
por: Das, Bibhuti B., et al.
Publicado: (2021)

Long-term evaluation of sperm parameters after coronavirus disease 2019 messenger ribonucleic acid vaccination
por: Diaz, Parris, et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination—A nationwide study
por: Su, Wei-Ju, et al.
Publicado: (2023)

Allergic reactions to the coronavirus disease 2019 vaccine (ARCOV) study: The McGill University Health Centre experience
por: ALMuhizi, Faisal, et al.
Publicado: (2022)

Antibody response to the messenger RNA corona virus disease 2019 vaccine in liver transplant recipients
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_639j42dac2r949g3e0a399qoug